Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00855647 · ClinicalTrials.gov registry record · Phase 2
Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 99,999
- Enrollment target
NCT00855647: Completed Phase 2 study, sponsored by Stanford University.
NCT00855647 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 99,999 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00855647, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99,999 participants
- Enrollment target
Study Summary
To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and effective in the treatment of low-risk localized prostate cancer.
Interventions
- PROCEDURE Hypo-fractionated Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99,999 participants |
| Start Date | 2003-08 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00855647
The ClinicalTrials.gov registry entry for NCT00855647 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99,999 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hypo-fractionated Radiotherapy is the first listed.
NCT00855647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00855647 about?
NCT00855647 is a clinical study titled "Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)". To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and effective in the treatment of low-risk localized prostate cancer.
What is the current status of trial NCT00855647?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99,999 participants. The study started on 2003-08. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00855647?
The interventions under investigation include: Hypo-fractionated Radiotherapy (PROCEDURE).
Who is sponsoring clinical trial NCT00855647?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.